Competitive Inhibition of Okanin against Plasmodium falciparum Tyrosyl-tRNA Synthetase
International Journal of Molecular Sciences · 26.04.2024 · 25 (9) · 4751
DOI: 10.3390/ijms25094751 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 26.04.2024. Verfasst von Guangpu Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Sun Yat-sen University, Shenzhen 518107, China. Hauptthemen laut MEDLINE: Plasmodium falciparum, Tyrosine-tRNA Ligase, Antimalarials, Molecular Docking Simulation. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Guangdong Natural Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Malaria is a severe disease that presents a significant threat to human health. As resistance to current drugs continues to increase, there is an urgent need for new antimalarial medications. Aminoacyl-tRNA synthetases (aaRSs) represent promising targets for drug development. In this study, we identified Plasmodium falciparum tyrosyl-tRNA synthetase (PfTyrRS) as a potential target for antimalarial drug development through a comparative analysis of the amino acid sequences and three-dimensional structures of human and plasmodium TyrRS, with particular emphasis on differences in key amino acids at the aminoacylation site. A total of 2141 bioactive compounds were screened using a high-throughput thermal shift assay (TSA). Okanin, known as an inhibitor of LPS-induced TLR4 expression, exhibited potent inhibitory activity against PfTyrRS, while showing limited inhibition of human TyrRS. Furthermore, bio-layer interferometry (BLI) confirmed the high affinity of okanin for PfTyrRS. Molecular dynamics (MD) simulations highlighted the stable conformation of okanin within PfTyrRS and its sustained binding to the enzyme. A molecular docking analysis revealed that okanin binds to both the tyrosine and partial ATP binding sites of the enzyme, preventing substrate binding. In addition, the compound inhibited the production of Plasmodium falciparum in the blood stage and had little cytotoxicity. Thus, okanin is a promising lead compound for the treatment of malaria caused by P. falciparum.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Public Health (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Sun Yat-sen University, Shenzhen 518107, China.
- Key Laboratory of Molecular Virology and Immunology, Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, Shanghai 200031, China.
- Shenzhen Key Laboratory of Pathogenic Microbes and Biosafety, Shenzhen 518107, China.
ORCID-Profile: Yunan Qian, Litao Sun
Förderung
- National Key Research and Development Program of China
- Guangdong Natural Science Foundation
- National Natural Science Foundation of China
- Shenzhen Science and Technology Innovation Commission
Zitieren
APA
Yang, G., Liang, Y., Li, X., Li, Z., Qin, Y., Weng, Q., Yan, Y., Cheng, Y., Qian, Y., & Sun, L. (2024). Competitive Inhibition of Okanin against Plasmodium falciparum Tyrosyl-tRNA Synthetase. International Journal of Molecular Sciences, 25(9), 4751. https://doi.org/10.3390/ijms25094751
Vancouver
Yang G, Liang Y, Li X, Li Z, Qin Y, Weng Q, et al. Competitive Inhibition of Okanin against Plasmodium falciparum Tyrosyl-tRNA Synthetase. International Journal of Molecular Sciences. 2024;25(9):4751. doi:10.3390/ijms25094751
BibTeX
@article{Yang2024,
author = {Yang, Guangpu and Liang, Yali and Li, Xiang and Li, Zan and Qin, Yinying and Weng, Qilu and Yan, Yujuan and Cheng, Yijun and Qian, Yunan and Sun, Litao},
title = {Competitive Inhibition of Okanin against Plasmodium falciparum Tyrosyl-tRNA Synthetase},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {9},
pages = {4751},
doi = {10.3390/ijms25094751}
}
EUVIMED